Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 388-400, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (29)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hon, Y. Y.
Right arrow Articles by Evans, W. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hon, Y. Y.
Right arrow Articles by Evans, W. E.
Related Collections
Right arrow Therapeutic Drug Monitoring Conference
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 1998;44:388-400.)
© 1998 American Association for Clinical Chemistry, Inc.

TDM Conference

Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach

Yuen Yi Hon, and William E. Evansa

a Author for correspondence. Fax (901) 525-6869;


Abstract

Several factors can limit the use of therapeutic drug monitoring (TDM) for cancer chemotherapeutic agents, including poorly defined concentration–effect relationships for many antineoplastic agents. This is further complicated by cancer being a highly heterogeneous group of diseases, each of which may have a unique concentration–effect relationship for any given drug or drug combination. Nonetheless, TDM clearly has the potential to improve the clinical use of antineoplastic agents, most of which have very narrow therapeutic indices and highly variable pharmacokinetics. A substantial body of literature accumulating during the past 15 years demonstrates relationships between systemic exposure to various anticancer drugs and their toxic or therapeutic effects. This review highlights selected studies that illustrate concentration–effect relationship for the antineoplastic effects of 5-fluorouracil, mercaptopurine, and methotrexate. A much larger number of pharmacodynamic studies have established the relationship between serum concentration and dose-limiting toxicities for anticancer agents, including epipodophyllotoxins, platinum compounds, camptothecin, anthracyclines, and antimetabolites. In this review we will focus on anticancer drugs for which the pharmacodynamics of antineoplastic effects have been elucidated. We will also address issues critical to the optimal use of TDM in a clinical setting, which requires effective participation by a multidisciplinary team of professionals.




The following articles in journals at HighWire Press have cited this article:


Home page
 J Oncol Pharm PractHome page
L. Alnaim
Therapeutic drug monitoring of cancer chemotherapy
Journal of Oncology Pharmacy Practice, December 1, 2007; 13(4): 207 - 221.
[Abstract] [PDF]

Home page
 The OncologistHome page
R. H.J. Mathijssen, F. A. de Jong, W. J. Loos, J. M. van der Bol, J. Verweij, and A. Sparreboom
Flat-Fixed Dosing Versus Body Surface Area Based Dosing of Anticancer Drugs in Adults: Does It Make a Difference?
Oncologist, August 1, 2007; 12(8): 913 - 923.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
J. L. Catalan-Aplandis, N. V. Jimenez-Torres, J. Calpe-Maravilla, and D. Almenar-Cubells
Gender and anthropometrics of patients undergoing cisplatin-containing chemotherapy as determinants of acute emesis over repeat courses
Journal of Oncology Pharmacy Practice, June 1, 2002; 8(2-3): 89 - 95.
[Abstract] [PDF]

Home page
 BloodHome page
S. A. Coulthard, C. Howell, J. Robson, and A. G. Hall
The Relationship Between Thiopurine Methyltransferase Activity and Genotype in Blasts From Patients With Acute Leukemia
Blood, October 15, 1998; 92(8): 2856 - 2862.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.